
Updated phase 1 data for micvotabart pelidotin, an antibody-drug conjugate that targets a protein in the tumor extracellular matrix, support Pyxis Oncology’s plan to start a phase 3 trial in recurrent/metastatic head and neck squamous cell carcinoma in mid-2027.








